On 4 July 2012, orphan designation (EU/3/12/1011) was granted by the European Commission to Emmaus Medical Europe Limited, United Kingdom, for levoglutamide for the treatment of sickle cell disease.
The sponsorship was transferred to Emmaus Medical Europe Limited, Ireland, in May 2019.
|Disease / condition||
Treatment of sickle cell disease
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;